Age reduces aspirin response
Nearly 600 patients with stable coronary artery disease, treated with aspirin 75–325mg/day for more than a week, were divided into two age groups and their aspirin response determined by the VerifyNow Aspirin Test.
Almost one in five patients in the over 75 group were resistant to the antiplatelet effects of aspirin, compared to one in 10 in the under 75 group.
“Elderly patients represent a growing segment of the cardiovascular population that is treated with long-term aspirin therapy,” the authors wrote. “This population is also